Pharmacological Reviews Get Tables of Contents delivered automatically
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Svensson, C. K.
Right arrow Articles by Gaspari, A. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Svensson, C. K.
Right arrow Articles by Gaspari, A. A.

Vol. 53, Issue 3, 357-380, September 2001

Cutaneous Drug Reactions

Craig K. Svensson1, Edward W. Cowen and Anthony A. Gaspari

Department of Pharmaceutical Sciences, Wayne State University, Detroit, Michigan (C.K.S.); and Department of Dermatology, University of Rochester, Rochester, New York (E.W.C., A.A.G.)

I. Epidemiology of Cutaneous Drug Reactions
II. Clinical Morphology of Cutaneous Drug Reactions
    A. Morbilliform Reactions
    B. Urticaria
    C. Fixed Drug Eruption
    D. Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis
III. Mechanisms of Cutaneous Drug Reactions
    A. Immediate-Type Immune-Mediated Drug Reactions
    B. Delayed-Type Immune-Mediated Drug Reactions
    C. Photosensitivity Reactions
        1. Phototoxicity.
        2. Photoallergy.
    D. Autoimmune Syndromes
IV. Role of Viral Infection as a Predisposing Factor for Cutaneous Drug Reactions
V. Cutaneous Drug Reactions Associated with Selected Drugs
    A. Sulfonamides
    B. Anticonvulsants
    C. Nonsteroidal Anti-Inflammatory Drugs
    D. Antiretroviral Agents
    E. Cephalosporins
    F. Ampicillin/Amoxicillin
Acknowledgments
References

Cutaneous drug reactions are the most frequently occurring adverse reactions to drugs. Among hospitalized patients, the incidence of these reactions ranges from 1 to 3%. The frequency of cutaneous reactions to specific drugs may exceed 10%. These reactions may range from mildly discomforting to those that are life-threatening. Anti-infective and anticonvulsant agents are among the drugs most commonly associated with adverse reactions in the skin. We describe and illustrate the clinical morphology of the most common cutaneous drug reactions, as well as drugs that most commonly precipitate specific reactions. The varied nature of the reactions that do occur, even with specific agents, indicates a multiplicity of mechanisms available whereby cutaneous drug reactions may be initiated. Although a variety of terms have been proposed for categorizing cutaneous drug reactions, we propose that reactions are best defined based upon mechanisms, where known. In this review, we assess the current knowledge of four categories of cutaneous drug reactions: immediate-type immune-mediated reactions, delayed-type immune-mediated reactions, photosensitivity reactions, and autoimmune syndromes. Moreover, we describe evidence that viral infection is an important predisposing factor for the development of cutaneous drug reactions upon drug administration. Finally, we review the current knowledge of the type and mechanisms of cutaneous drug reactions to several categories of drugs.


1 Address for correspondence: Dr. Craig K. Svensson, Department of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202. E-mail: cks{at}wizard.pharm.wayne.edu


0031-6997/01/5303-0357$03.00/0
PHARMACOLOGICAL REVIEWS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
W. Song and W. A. Miller
Diffuse exanthema in a patient receiving varenicline
Am. J. Health Syst. Pharm., July 1, 2008; 65(13): 1239 - 1241.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
F. D. Khan, P. M. Vyas, A. A. Gaspari, and C. K. Svensson
Effect of Arylhydroxylamine Metabolites of Sulfamethoxazole and Dapsone on Stress Signal Expression in Human Keratinocytes
J. Pharmacol. Exp. Ther., December 1, 2007; 323(3): 771 - 777.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
S. Roychowdhury, P. M. Vyas, and C. K. Svensson
Formation and Uptake of Arylhydroxylamine-Haptenated Proteins in Human Dendritic Cells
Drug Metab. Dispos., April 1, 2007; 35(4): 676 - 681.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. M. Vyas, S. Roychowdhury, F. D. Khan, T. E. Prisinzano, J. Lamba, E. G. Schuetz, J. Blaisdell, J. A. Goldstein, K. L. Munson, R. N. Hines, et al.
Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: I. Expression and Role of Cytochromes P450
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 488 - 496.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. M. Vyas, S. Roychowdhury, S. B. Koukouritaki, R. N. Hines, S. K. Krueger, D. E. Williams, W. M. Nauseef, and C. K. Svensson
Enzyme-Mediated Protein Haptenation of Dapsone and Sulfamethoxazole in Human Keratinocytes: II. Expression and Role of Flavin-Containing Monooxygenases and Peroxidases
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 497 - 505.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
R. N. Saladi, S. R. Cohen, R. G. Phelps, A. N. Persaud, and D. Rudikoff
Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature.
Arch Dermatol, February 1, 2006; 142(2): 206 - 210.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. Roychowdhury, P. M. Vyas, T. P. Reilly, A. A. Gaspari, and C. K. Svensson
Characterization of the Formation and Localization of Sulfamethoxazole and Dapsone-Associated Drug-Protein Adducts in Human Epidermal Keratinocytes
J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 43 - 52.
[Abstract] [Full Text] [PDF]


Home page
Crit. Rev. Oral Biol. Med.Home page
L. A. Torpet, C. Kragelund, J. Reibel, and B. Nauntofte
ORAL ADVERSE DRUG REACTIONS TO CARDIOVASCULAR DRUGS
Crit. Rev. Oral. Biol. Med., January 1, 2004; 15(1): 28 - 46.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition